Client News
Expedeon AG: Expedeon AG and Abcam plc close EUR 120 million transaction
2nd January 2020
MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.
31st December 2019
Expedeon shareholders approve sale of proteomics & immunotherapy business and name change to 4basebio AG
19th December 2019
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial
18th December 2019
Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
18th December 2019
Lindis Blood Care GmbH: Over 5 million euros for Lindis Blood Care – development of a new product for the removal of tumor cells from surgical blood
11th December 2019
SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia
10th December 2019
Motif Bio plc: Confirmation of timing of voluntary delisting from the NASDAQ Capital Market
10th December 2019
There is no more content to load